On Monday, Beam Therapeutics Inc (NASDAQ: BEAM) was -3.53% drop from the session before settling in for the closing price of $26.32. A 52-week range for BEAM has been $13.52 – $35.25.
Annual sales at Healthcare sector company slipped by -20.88% over the past five years. When this article was written, the company’s average yearly earnings per share was at 5.33%. With a float of $91.27 million, this company’s outstanding shares have now reached $100.76 million.
Let’s look at the performance matrix of the company that is accounted for 483 employees.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Beam Therapeutics Inc stocks. The insider ownership of Beam Therapeutics Inc is 9.78%, while institutional ownership is 101.27%. The most recent insider transaction that took place on Oct 01 ’25, was worth 11,456. In this transaction SVP, Finance and Treasurer of this company sold 467 shares at a rate of $24.53, taking the stock ownership to the 44,045 shares. Before that another transaction happened on Oct 01 ’25, when Company’s Chief Legal Officer sold 373 for $24.53, making the entire transaction worth $9,150. This insider now owns 116,921 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1.17 earnings per share (EPS) during the time that was better than consensus figure (set at -1.18) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.31% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
You can see what Beam Therapeutics Inc (BEAM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 42.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.51, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -4.42 in one year’s time.
